骨髓衍生抑制细胞:对于胃肠道癌症的治疗目标
Junaid Arshad1, Amith Rao2, Matthew L Repp3
1University of Arizona Cancer Center, GI Medical Oncology, Tucson, AZ 85724, USA.
International journal of molecular sciences
|March 13, 2024
概括
骨髓衍生抑制细胞 (MDSCs) 是胃肠道癌症的关键驱动因素. 针对MDSCs为这些具有挑战性的恶性瘤提供了一个有希望的新治疗策略.
科学领域:
- 瘤学 在瘤学方面.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 胃肠道 (GI) 癌症很难用当前的方法治疗.
- 瘤微环境对于胃肠道癌症的进展至关重要.
- 骨髓系衍生抑制细胞 (MDSCs) 显著影响肠胃癌的发病性.
研究的目的:
- 分析MDSCs在肠道癌症中的作用.
- 确定MDSC作为潜在的治疗点.
- 审查针对MDSCs的新型胃肠道癌症治疗方法的临床试验环境.
主要方法:
- 在胃肠道癌症中MDSC功能的文献综述.
- 对定义MDSC目标的临床前模型的分析.
- 对MDSC向疗法的已完成和正在进行的临床试验的审查.
主要成果:
- MDSCs是肠道癌症进展的关键驱动因素.
- 针对MDSCs存在多种策略,包括阻止招募,促进差异化,耗尽,代谢改变和直接功能抑制.
- 越来越多的临床试验正在调查针对MDSC的新型治疗方法.
结论:
- MDSCs代表了GI恶性瘤的一个可行的和重要的治疗标.
- 准MDSC有望改善肠道癌的治疗结果.
- 进一步的研究和临床试验对于充分实现MDSC向疗法的潜力至关重要.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163


